The factorial architecture is the trial’s defining technical feature. Rather than comparing a single combined treatment against a control, the investigators treat acupuncture and moxibustion as two independent randomized factors, each present or absent. Every participant receives standard oral estradiol/dydrogesterone therapy, marketed as Femoston, following a sequential 28-day regimen: one milligram of estradiol daily for the first 14 days, then one milligram of estradiol plus 10 milligrams of dydrogesterone daily for the following 14 days, providing both hormone replacement and endometrial protection. On top of this common hormonal background, women are assigned in a 1:1:1:1 ratio to Femoston alone, acupuncture plus Femoston, moxibustion plus Femoston, or combined acupuncture and moxibustion plus Femoston, with 36 participants in each group.

This design allows statisticians to estimate the main effect of acupuncture by pooling the two groups that receive it, 72 participants, against the 72 who do not, and to do the same for moxibustion. The acupuncture × moxibustion interaction, whether the two modalities amplify or interfere with one another, will also be estimated but is explicitly exploratory, because the trial was not powered specifically for that question. The investigators argue that this structure resolves an ambiguity that plagues conventional three-arm comparisons: if a combined treatment outperforms a control, it is often unclear whether the benefit arises from one component, the other, or their synergy. The factorial design disentangles those possibilities within a single trial.

The primary outcome is the change from baseline to week 12 in antral follicle count, or AFC, the total number of 2 to 9 millimeter antral follicles visible in both ovaries on transvaginal ultrasound. AFC provides a direct ultrasound-based estimate of the recruitable follicle pool and is a clinically recognized marker of ovarian reserve. The 12-week window was chosen on empirical grounds: a prior randomized study in women with POI reported measurable increases in both AFC and anti-Müllerian hormone after a comparable three-month estradiol/dydrogesterone regimen with or without adjunct acupuncture, and a recent 12-week sham-controlled trial in women with diminished ovarian reserve found that acupuncture three times weekly produced significantly greater AFC improvement than sham, although the between-group AMH difference was not statistically significant. Importantly, the protocol cautions that a biomarker change at 12 weeks should not be interpreted as restoration of the primordial follicle pool or of fertility.

Secondary outcomes span the multidimensional clinical burden of POI. Serum anti-Müllerian hormone will be measured in a central laboratory using the Roche Elecsys AMH assay on a cobas e 602 electrochemiluminescence platform, with fasting blood samples processed within two hours, centrifuged, aliquoted, stored at minus 80 degrees Celsius, and transported on dry ice from the three recruitment centers to minimize inter-laboratory variability. Follicle-stimulating hormone, luteinizing hormone, and estradiol will be measured by chemiluminescent immunoassay. Transvaginal color Doppler ultrasound will capture ovarian hemodynamic parameters, including peak systolic velocity, resistance index, and pulsatility index. Patient-reported measures include the modified Kupperman Scale for hypoestrogenic symptoms, the Self-Rating Anxiety Scale for psychological distress, Traditional Chinese Medicine syndrome scores, and menstrual status, all assessed at baseline and week 12.

Clinical pregnancy, defined as an intrauterine gestational sac with fetal cardiac activity confirmed by ultrasound, will be analyzed as an exploratory reproductive outcome recorded during treatment and at follow-up visits at weeks 24 and 48. The trial was not powered for pregnancy endpoints, and the investigators emphasize that conception during follow-up may be strongly influenced by subsequent ovulation induction, in vitro fertilization and embryo transfer, or other assisted reproductive technology. Post-randomization summaries of spontaneous conceptions versus conceptions following ART will be regarded as exploratory rather than randomized causal comparisons. Participants who become pregnant will discontinue acupuncture and moxibustion immediately and transfer to pregnancy follow-up.

The intervention protocol is standardized in unusual technical detail. The acupuncture prescription comprises two alternating treatment sets: set A, performed in the supine position, includes abdominal points CV12, CV6, CV4, bilateral ST25, ST29, EX-CA1, and leg points ST36, SP6, and LR3; set B, performed prone, includes bilateral BL23, BL32, and KI3. Needles of 0.25 by 40 millimeters and 0.30 by 75 millimeters are inserted to prespecified depths, with BL32 advanced obliquely toward the second posterior sacral foramen to 60 to 75 millimeters. Gentle lifting, thrusting, and twirling elicit Deqi, the characteristic sensation of soreness, numbness, distension, or heaviness, and needles are retained for 30 minutes. The moxibustion arm applies self-adhesive moxa column patches, each burning roughly 10 minutes, to the identical acupoints without needle insertion, three columns per session for approximately 30 minutes. In the combined group, moxibustion is applied during needle retention after Deqi is achieved. Both external therapies are delivered three times weekly for 12 weeks, totaling 36 sessions.

Because acupuncture and moxibustion are physical interventions, participants and practitioners cannot be blinded, so the trial adopts an assessor-blinded design. Recruitment and screening personnel are separated from treatment practitioners, who play no role in outcome assessment. Outcome assessors, ultrasound physicians, laboratory technicians, data-entry staff, and statisticians remain blinded to allocation throughout. To minimize measurement variability, all baseline and week-12 AFC examinations, regardless of recruitment center, will be performed centrally in the ultrasound department of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine using a GE HealthCare LOGIQ Fortis system with an RIC5-9-D transvaginal volume probe, and the same blinded physician will examine the same participant whenever feasible. Adverse events, including vasovagal reactions, hematomas, burns, and hormone-related symptoms such as breast tenderness and abnormal bleeding, will be recorded with a four-level severity grading scheme, and serious events reported to the ethics committee within 24 hours.

The sample size was planned from prior literature in which post-treatment AFC was 3.97 plus or minus 1.15 in the Femoston-only group and 5.14 plus or minus 1.33 in the acupuncture plus Femoston group, a between-group difference of 1.17 corresponding to Cohen’s d of approximately 0.94. G*Power calculations with 90 percent power and a two-sided alpha of 0.05 indicated 26 participants per group, increased to 36 per group to allow for roughly 20 percent dropout, for a total of 144. Within the factorial framework, each factor level includes up to 72 participants, yielding greater than 99 percent power to detect a main effect of that magnitude, with a minimum detectable standardized effect of approximately 0.54 at 90 percent power. The investigators stress that the planning benchmark derived from an acupuncture comparison does not imply the true moxibustion effect equals d of 0.94.

The trial’s eligibility criteria deliberately define a selected subgroup: women aged 22 to 40 with reproductive needs, basal FSH between 25 and 40 U/L confirmed on two occasions at least four weeks apart, and recruitment during the pretreatment phase before assisted reproduction. The investigators acknowledge that these criteria limit generalizability to adolescents, women with more advanced ovarian failure, those without fertility intentions, or patients with substantial comorbidity. The absence of sham controls means subjective outcomes such as anxiety and TCM syndrome scores may reflect treatment expectations and practitioner attention as well as specific physiological effects, although more objective biomarkers like AFC and AMH are less directly susceptible to such contextual influences. Registered with the International Traditional Medicine Clinical Trial Registry under identifier ITMCTR2025002408 and approved by the ethics committee of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, the trial may clarify whether either modality is associated with changes in ovarian reserve markers when added to standard hormone therapy, and may generate preliminary evidence on their potential interaction, providing a methodological basis for future larger trials designed around definitive reproductive outcomes such as live birth.

Subject of Research: Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial

Article Title: Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial

Article References: Lu, C., Ye, T., Cui, J., & Chen, B. (2026). Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial. Frontiers in Endocrinology, 17, Article 1952726. https://doi.org/10.3389/fendo.2026.1952726

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1952726

Keywords: acupuncture, moxibustion, premature ovarian insufficiency, hormone replacement therapy, factorial randomized controlled trial, reproductive medicine, Adjunctive, effects, women, premature, ovarian, insufficiency

The study, led by Yu Song and Xinyu Zhou of the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, together with colleagues in the hospital’s Respiratory Intensive Care Unit, set out to answer a question that individual trials could not. Dozens of small randomized controlled trials have tested various TCM-based interventions against cancer-related fatigue, but results were scattered across different techniques, patient groups and outcome measures, leaving clinicians with no clear sense of which therapy deserved priority. By pooling all of the evidence in a single statistical framework, the researchers hoped to rank the treatments even where no trial had ever compared them directly.

To do this, the team searched eight electronic databases from their inception up to 24 November 2025, screening the literature for randomized controlled trials that evaluated TCM-based non-pharmacological therapies in lung cancer patients and reported fatigue outcomes. The methodological quality of each included trial was assessed with the Cochrane Risk of Bias 2.0 tool, the current standard for judging whether a trial’s design and conduct could plausibly distort its results. All statistical analyses were performed in STATA 18.0, and the synthesis followed the PRISMA extension statement designed specifically for network meta-analyses, the reporting framework that allows both direct and indirect comparisons to be combined coherently.

The final evidence base comprised 32 randomized controlled trials covering eight distinct TCM-based non-pharmacological therapies. The list reads like a tour of classical Chinese medicine adapted for the modern oncology ward: moxibustion in several forms, including thunder-fire and heat-sensitive variants; auricular acupressure, in which seeds or needles are pressed into points on the outer ear; acupuncture and acupressure; transcutaneous electrical acupoint stimulation, known as TEAS; qigong and related mind-body exercises such as Baduanjin, Tai Chi, Liuzijue and Wuqinxi; acupoint application of herbal plasters; and traditional techniques such as hot ironing and drug canister therapy. Rather than comparing each therapy only against usual care, the network meta-analysis placed them all on a common scale, using standardized mean differences to express how much each reduced fatigue relative to the alternatives.

The headline result concerns moxibustion. Against usual care, moxibustion achieved a standardized mean difference of −2.56, with a 95 percent confidence interval spanning −3.60 to −1.51. In plain terms, patients receiving moxibustion reported substantially lower fatigue scores than those receiving routine care, and the effect size is large by any clinical convention — standardized mean differences above 0.8 are typically considered large, so a value exceeding two represents an unusually pronounced signal. Auricular acupressure also beat usual care significantly, with a standardized mean difference of −1.82 (95 percent CI −3.61 to −0.03), although the confidence interval only just excludes zero, indicating a more fragile statistical foundation.

Perhaps more consequential is the direct comparison between therapies. Moxibustion showed a significant advantage over qigong, with a standardized mean difference of −2.12 (95 percent CI −3.58 to −0.65). This is notable because qigong and its cousins Tai Chi and Baduanjin are the TCM-based interventions most familiar to Western integrative oncology, and they have accumulated a respectable evidence base in other cancers. The finding does not mean qigong is useless — the analysis simply found it less effective than moxibustion for fatigue specifically in lung cancer patients — but it does suggest that passive heat-based stimulation of acupuncture points may outperform movement-based practices for this symptom in this population, at least within the current trial literature.

Why might moxibustion perform so well? The therapy involves burning processed mugwort, either on or hovering just above selected acupuncture points, delivering sustained radiant heat to the skin. Trials included in the review tested several refinements, from temperature-controlled thunder-fire moxibustion to heat-sensitive moxibustion, in which practitioners identify points that respond unusually to warmth, and herbal cake moxibustion applied to the back Shu points. Proposed mechanisms are largely indirect: heat stimulation may modulate local blood flow, influence immune parameters — some trials in the review tracked lymphocyte counts and immune function — and alter signaling in pathways implicated in the biology of cancer-related fatigue, which is thought to involve inflammation, hypothalamic-pituitary-adrenal dysregulation and disrupted energy metabolism. Auricular acupressure, meanwhile, has a plausible neurological rationale, since stimulation of the ear’s vagal distribution can influence autonomic balance, a mechanism explored in related work on transcutaneous auricular vagus nerve stimulation.

The authors themselves temper enthusiasm with an important caveat. The included trials showed considerable risk of bias, a common problem in the complementary medicine literature where true placebos are difficult to design — patients and practitioners inevitably know whether mugwort is being burned on their skin, and blinding of outcome assessors is often incomplete. Small sample sizes, heterogeneous intervention protocols and variable fatigue measurement instruments further weaken the evidence. The review’s conclusion is therefore deliberately cautious: moxibustion and auricular acupressure may be the most promising TCM-based non-pharmacological therapies for alleviating cancer-related fatigue in lung cancer patients, qigong appears less effective, but these conclusions require validation through more rigorously designed, high-quality clinical trials before they can guide practice with confidence.

Context matters for interpreting the stakes. Lung cancer remains the leading cause of cancer death worldwide, and fatigue is among its most prevalent and disabling symptoms, reported during palliative chemotherapy and long after treatment ends. Qualitative studies show that patients describe the exhaustion as qualitatively different from everyday tiredness, shaping their depression, anxiety and willingness to continue treatment. Because fatigue also independently predicts reduced health-related quality of life in lung cancer survivors, an inexpensive, low-risk, non-drug therapy that meaningfully reduces it would be a genuine addition to supportive care — particularly if it can be delivered by nurses as part of routine symptom management, as many of the included trials envisioned.

For now, the study offers both a roadmap and a warning. The roadmap points researchers toward moxibustion and auricular acupressure as priority interventions deserving large, well-blinded, preregistered trials with standardized fatigue instruments and adequate follow-up. The warning is that a network meta-analysis is only as reliable as the trials feeding it, and 32 small studies with elevated risk of bias can inflate or distort rankings in ways that only better primary research can resolve. Patients and clinicians should read the result as a promising signal rather than a prescription: the ancient practice of warming acupuncture points with burning mugwort may yet earn a modern place in oncology supportive care, but the definitive trials that would justify it have still to be run.

Subject of Research: Comparative efficacy of Traditional Chinese Medicine-based non-pharmacological therapies for cancer-related fatigue in lung cancer patients

Article Title: Comparative efficacy of traditional Chinese medicine-based non-pharmacological therapies for managing cancer-related fatigue in lung cancer patients: a systematic review and network meta-analysis

Article References: Song, Y., Zhou, X., Luo, Y., Guo, H., Xia, Y., Ni, F., & Geng, S. (2026). Comparative efficacy of traditional Chinese medicine-based non-pharmacological therapies for managing cancer-related fatigue in lung cancer patients: a systematic review and network meta-analysis. Supportive Care in Cancer, 34(10), Article 984. https://doi.org/10.1007/s00520-026-11208-6

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11208-6

Keywords: cancer-related fatigue, lung cancer, moxibustion, auricular acupressure, Traditional Chinese Medicine, network meta-analysis, qigong, acupuncture, non-pharmacological therapies, supportive care, randomized controlled trials, systematic review

The study, led by Hiroto Ishiki of the Department of Palliative Medicine at the National Cancer Center Hospital in Tokyo and published in the journal Supportive Care in Cancer, examined a program the researchers call multimodal Japanese-style acupuncture and moxibustion, abbreviated MJAM. Unlike a single-technique acupuncture session, MJAM is a composite intervention that weaves together several distinct components: filiform needle acupuncture, in which fine needles are inserted into the skin; non-insertive needle therapy using a Teishin, a blunt instrument pressed against the skin without puncturing it; motion-style acupuncture, in which needling is combined with guided movement of the affected limb; indirect moxibustion, which applies the gentle heat of burning mugwort above the skin; hot pack application; and structured self-care instruction that patients continue at home.

The rationale for testing such a program rests on a substantial body of evidence suggesting that acupuncture can modulate chronic pain. Individual patient data meta-analyses have shown that acupuncture outperforms both sham procedures and usual care for chronic musculoskeletal pain, and systematic reviews have associated acupuncture and acupressure with improved cancer pain outcomes. Yet the picture for CIPN specifically has remained murky. Randomized trials of acupuncture for CIPN, including a large sham-controlled trial published in JAMA Network Open, have produced mixed results, and international guidelines from ASCO and ESMO currently offer few validated options for treating established CIPN, with duloxetine being one of the only pharmacological approaches supported by randomized evidence.

To explore whether the Japanese multimodal approach might help, the researchers conducted a single-center, single-arm study at the National Cancer Center Hospital. They enrolled women who had completed curative treatment for stage I to III breast cancer at least three months earlier and who were experiencing moderate to severe taxane-related CIPN pain, defined as a score of 4 or greater on item 5 of the Brief Pain Inventory, a validated instrument that asks patients to rate their average pain on a scale from 0 to 10. Between October 2022 and April 2024, 30 women with a median age of 58.0 years joined the study. On average, these patients were not fresh out of chemotherapy: the median time since completing treatment was 2.47 years, meaning their neuropathy had become a chronic, entrenched problem rather than a transient side effect.

Each participant received 12 weekly sessions of the standardized MJAM program, delivered over roughly three months. The researchers then tracked outcomes through week 16, four weeks after the final session, to see whether any benefit would persist beyond the treatment period itself. The primary endpoint was the change in the Brief Pain Inventory item 5 score, the patient’s rating of average pain, from baseline to week 16. At the start of the study, the mean baseline score was 5.3, with a standard deviation of 1.7, indicating that most participants were living with pain that was more than moderate on a daily basis.

The results showed a clear and statistically significant decline in pain over the course of the program. At week 4, after roughly a month of sessions, the mean change from baseline was only −0.1 points, a difference that could easily have arisen by chance, with a 95 percent confidence interval ranging from −0.6 to 0.3 and a p-value of 0.56. But by week 8, the mean reduction had grown to −0.7 points, a change that reached statistical significance. By week 12, the mean reduction was −1.1 points, and at the primary endpoint of week 16 it stood at −1.2 points, with a 90 percent confidence interval of −1.7 to −0.8 and a p-value below 0.0001. Notably, the benefit continued to accrue after the final session, suggesting that the effects of the program did not evaporate the moment treatment stopped.

The magnitude of the improvement matters as much as its statistical significance. In chronic pain research, the consensus recommendations from the IMMPACT initiative suggest that a reduction of roughly one point on a 0-to-10 pain scale can be clinically meaningful, and a drop of about 1.2 points on the Brief Pain Inventory average pain item approaches the thresholds often considered clinically important. For patients whose pain had persisted for more than two years after chemotherapy, a sustained reduction of this size, achieved without adding any new medication, represents a meaningful shift in daily comfort, even if it does not amount to a cure.

Safety and feasibility were equally central to the study’s conclusions. Twenty-eight of the 30 participants, or 93.3 percent, completed all 12 sessions, an adherence rate that speaks to the tolerability of the program and the practicality of weekly visits. Adverse events were uncommon and uniformly mild: nine participants, or 30.0 percent, experienced grade 1 events, the lowest severity category, with no serious harms reported. For a population of cancer survivors who are often wary of adding further interventions to their care, this safety profile is an important part of the story.

The researchers are careful to frame these findings as preliminary rather than definitive. Because the study was single-arm, with no control group, there is no way to rule out explanations such as the natural course of the condition, regression to the mean, or a strong placebo response, all of which are particularly relevant in pain research, where patient expectations can powerfully shape reported outcomes. The relatively small sample of 30 women and the single-center design further limit how far the results can be generalized. What the study does establish is that MJAM is safe, feasible, and associated with a reduction in pain severe enough to justify the confirmatory randomized clinical trial that the authors say is warranted.

Even so, the trial occupies an important position in a growing research landscape. Electroacupuncture trials for taxane-induced neuropathy are underway, pragmatic trials of acupuncture added to standard care have shown signals of benefit, and dose-response meta-analyses are beginning to explore how the timing and frequency of acupuncture sessions influence outcomes in CIPN. Integrative oncology guidelines from the Society for Integrative Oncology and ASCO already encourage the consideration of acupuncture for pain management in cancer care. If a rigorous randomized trial confirms what this exploratory study suggests, a centuries-old Japanese practice, refined with modern standardization and delivered alongside self-care education, could become a genuine option for the many breast cancer survivors whose nerve pain has, until now, had nowhere to go.

Subject of Research: Multimodal Japanese-style acupuncture and moxibustion as a treatment for taxane-related chemotherapy-induced peripheral neuropathy in breast cancer survivors

Article Title: Multimodal Japanese-style acupuncture and moxibustion for taxane-related chemotherapy-induced peripheral neuropathy in breast cancer survivors

Article References: Ishiki, H., Satomi, E., Matsuoka, H., Arakawa, S., Kawasaki, N., Horiguchi, Y., Takahashi, A., Takagi, T., Kobayashi, S., Oyamada, S., Ariyoshi, K., Kihara, K., Suto, A., Murata, T., & Takayama, S. (2026). Multimodal Japanese-style acupuncture and moxibustion for taxane-related chemotherapy-induced peripheral neuropathy in breast cancer survivors. Supportive Care in Cancer, 34(10), Article 997. https://doi.org/10.1007/s00520-026-11237-1

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11237-1

Keywords: chemotherapy-induced peripheral neuropathy, breast cancer, acupuncture, moxibustion, taxanes, pain management, survivorship, integrative oncology, clinical trial, non-pharmacological therapy, Brief Pain Inventory, Japan

Trichomes are epidermal appendages found across most flowering plants, as well as some gymnosperms and bryophytes, and they take an astonishing variety of forms, from cucumber fruit spines to cotton fibers. Botanists divide them into two broad classes. Glandular secretory trichomes manufacture and store volatile compounds, resins, and other metabolites, while non-glandular trichomes lack secretory activity but provide crucial physical defense, reducing water loss through transpiration, capturing moisture from fog, buffering against temperature extremes, and shielding leaf tissue from ultraviolet radiation and herbivores. Most of what science knows about non-glandular trichome development comes from unicellular systems such as Arabidopsis rosette leaves and cotton fibers, where each hair arises from a single epidermal cell. Multicellular non-glandular trichomes, by contrast, have lacked a workable model system, leaving a significant gap in plant developmental biology.

Artemisia argyi, a perennial herb in the Asteraceae family, turns out to be an unusually elegant model for closing that gap. Scanning electron microscopy performed by the team revealed a striking asymmetry: the upper leaf surface is dominated by slipper-shaped glandular trichomes measuring roughly 33.3 by 52.1 micrometers, while the lower surface is carpeted with elongated T-shaped trichomes whose branched arms exceed one millimeter in length and intertwine into a dense mat. The stalks of these T-shaped hairs are short, about 28.8 micrometers, but their asymmetrical arms give the structure its name and its function. This clean separation of trichome types between the two leaf surfaces gives researchers a natural experiment in epidermal patterning, and it explains why the species has become a defining subject for studying multicellular hair development.

The commercial stakes are considerable. Mugwort’s dried leaves are the primary medicinal material documented in the Chinese Pharmacopoeia for warming the meridians, stopping bleeding, dispelling cold, and relieving pain, and the sector exceeded 30 billion yuan in industrial output in 2023. Moxa floss, the fibrous product central to moxibustion, consists primarily of these leaf trichomes, and its efficacy is attributed not only to combustion heat but to bioactive volatile compounds released from trichome tissue. Because trichome abundance and morphology directly determine floss yield and quality, understanding the genes that control hair formation has immediate implications for breeding improved cultivars of a plant whose germplasm is distributed across China, Mongolia, and North Korea.

To find those genes, the researchers manually separated T-shaped trichomes from the remaining leaf tissue and sequenced the transcriptomes of both, generating 39.03 gigabases of clean reads mapped to a reference genome at rates between 74.30 and 97.15 percent. The comparison was dramatic: 8,901 genes were upregulated and 4,698 downregulated in the trichome fraction. Gene Ontology enrichment pointed toward membrane components, the plasma membrane, and defense responses, while KEGG analysis flagged pathways including MAPK signaling and isoflavonoid and flavonoid biosynthesis. Several transcription factor families long associated with trichome development, including R2R3-MYB, C2H2 zinc-finger, HD-ZIP IV, bHLH, ethylene-responsive, and WD40 repeat proteins, were markedly enriched in the hairs, confirming that the sequencing had captured a genuine developmental signature rather than random tissue noise.

The team then widened the lens, integrating public RNA-seq datasets from old leaves, young leaves, stems, and glandular trichomes with their own data in a Weighted Correlation Network Analysis covering 53,354 genes. Five co-expression modules emerged, and one, the cyan module, stood out for its enrichment in cutin biosynthetic genes and homologs of known Arabidopsis trichome regulators. Within that module’s network, members of a family the authors named AarMIXTAs behaved as hub genes, strongly connected to MYB, bHLH, WD40, HD-ZIP, and WRKY factors. Homology-based screening against well-characterized regulators from Arabidopsis and the related species Artemisia annua identified 119 mugwort genes tied to trichome development across 27 allelic groups, with evidence of tandem duplication for some genes such as ETC1, TT8, and EGL3, and allelic amplification for others including TTG1, RGA, and the MIXTAs themselves.

The evolutionary story proved to be the most striking finding. Drawing on 144 MIXTA and MIXTA-like protein sequences from NCBI and Phytozome databases, spanning 136 angiosperms, two gymnosperms, and six ANA-grade outgroups, the researchers built a maximum likelihood phylogeny that resolved into four major clades. The gymnosperm sequences occupied the most ancestral position, monocots clustered separately, and two dicot-only clades containing 33 and 77 proteins appeared to have descended from the earlier lineages. Within this framework, mugwort stood out: its genome harbors eight AarMIXTA genes, a substantial expansion compared with A. annua. These fell into two clades, one most closely related to lettuce and the other to A. annua, suggesting the duplication events occurred after the Asteraceae lineage diverged from other eudicots. Elevated synonymous substitution rates between the clades hinted at accelerated evolution, possibly driven by local recombination, relaxed selection, or positive selection following segmental or tandem duplication.

Crucially, the duplicated genes did not simply do the same job twice. Although the AarMIXTAs share conserved exon-intron structures and high sequence similarity with their A. annua homologs, their expression patterns diverged sharply. The clade comprising AarMIXTA1.1 through 1.4 was expressed at significantly higher levels in T-shaped trichomes, while AarMIXTA1.5 through 1.8 were more abundant in glandular trichomes. Since AanMIXTA1 in A. annua is a validated positive regulator of glandular trichome density and artemisinin biosynthesis, its mugwort relatives in the second clade likely inherited that role. The first clade, occupying a distinct phylogenetic position, appears to have been recruited for a different task: building the non-glandular, T-shaped hairs that define the species. This is a textbook case of neofunctionalization after gene duplication, likely facilitated by the polyploid history of A. argyi, which is an autotetraploid.

Functional validation sealed the argument. The team selected AarMIXTA1.2, whose expression rises progressively during leaf development and peaks specifically in T-shaped trichomes, and overexpressed it in Arabidopsis under the 35S promoter. The transgenic plants showed two clear phenotypic changes: increased total leaf number and a roughly twofold increase in trichome density, along with moderately longer trichome branches and stalks. Quantitative PCR revealed that core Arabidopsis trichome regulators, including AtGL2, AtTAR2, AtMYB23, AtTTG1, and AtHD1, were all significantly upregulated in the transgenic lines, and the native AtMIXTA gene was elevated as well, hinting at feedback or synergistic interactions. The results demonstrate that a single mugwort transcription factor can activate a conserved downstream cascade and reshape epidermal patterning even in a distantly related species.

The implications extend well beyond mugwort. For developmental biologists, the study establishes A. argyi as a model for multicellular non-glandular trichome development, a process long overshadowed by unicellular systems, and shows that the ancient MIXTA toolkit, first cloned from snapdragon in 1994 as a controller of petal cell shape, has been repeatedly redeployed across plant evolution to sculpt epidermal surfaces. For the mugwort industry, the AarMIXTA family offers molecular markers for breeding varieties with denser, higher-quality trichomes, potentially through targeted genetic screening and trait selection. The authors point to next steps including yeast two-hybrid screens for AarMIXTA1.2 interactors, epigenetic and chromatin accessibility studies, and functional testing in mugwort itself. They also raise an intriguing ecological question: whether the plant’s remarkable environmental adaptability across diverse Chinese habitats owes something to its trichome armor, connecting a millennia-old therapeutic tradition to the frontiers of modern plant genetics.

Subject of Research: Genetic regulation of T-shaped non-glandular trichome development in Artemisia argyi by MIXTA-like transcription factors

Article Title: Functional characterization of AarMIXTAs as essential regulators in T-shaped non-glandular trichome development of Artemisia argyi

Article References: Chen, X., Wu, D., Li, C., Liao, B., & Shen, Q. (2025). Functional characterization of AarMIXTAs as essential regulators in T-shaped non-glandular trichome development of Artemisia argyi. Advanced Biotechnology, 3(3), Article 26. https://doi.org/10.1007/s44307-025-00077-5

Image Credits: AI Generated

DOI: 10.1007/s44307-025-00077-5

Keywords: Artemisia argyi, trichome development, AarMIXTA, transcription factors, moxibustion, moxa floss, gene duplication, polyploidy, Arabidopsis, comparative transcriptomics, WGCNA, plant morphogenesis

The technique itself is worth understanding, because it is more mechanically demanding than it first appears. Warm needle acupuncture combines acupuncture, the insertion of fine needles into specific points on the body, with moxibustion, the burning of dried mugwort near or on the skin to deliver radiant heat. In the warm needle variant, a small ball or cylinder of moxa is attached directly to the shaft of an inserted needle and ignited. Heat travels down the conductive metal shaft to the tip, delivering warmth deep into the tissue at the insertion point. Practitioners regard this as a way of intensifying the stimulation of acupuncture points, particularly for conditions associated with cold sensitivity, chronic pain, and musculoskeletal stiffness. The procedure, however, demands constant attention: the moxa must be sized and positioned correctly, the burning material must not scald the skin, smoke must be managed, and the needle must be monitored until the heat dissipates. Every one of those steps is an opportunity for error, and every one of them takes time.

To map how the profession actually uses this technique, the researchers conducted a web-based survey between September 27 and November 3, 2025, inviting all 28,319 licensed Korean Medicine doctors in the country to participate. A total of 1,076 completed the questionnaire, a sample large enough to support meaningful subgroup analysis across age brackets, career stages, and practice settings. Respondents were asked whether they used warm needle acupuncture, how often, for which conditions, whether they had encountered adverse events, what prevented more frequent use, and what kinds of devices, training, or reimbursement changes they would like to see. The study was reviewed and granted an exemption by the Institutional Review Board of Dongguk University Oriental Hospital and conducted in line with the Declaration of Helsinki, with electronic informed consent from all participants.

The headline finding is that warm needle acupuncture is far from marginal. Among the 1,076 respondents, 68.7 percent reported using it in clinical practice, a striking adoption rate for a procedure that requires hands-on fire management in an era of standardized, single-use needles. The subgroup analyses added an important nuance: utilization rose steadily with both clinical experience and age. Older, more seasoned practitioners were considerably more likely to reach for the moxa and the matches than their younger colleagues. That pattern cuts two ways. It suggests the technique’s value is learned and confirmed through years of practice, but it also hints at a generational drift, in which newer graduates trained in a more proceduralized, risk-averse clinical environment may be quietly letting the skill atrophy.

Then comes the number that will draw the most attention: among the 739 respondents who had actually used warm needle acupuncture, 87.8 percent reported having encountered at least one adverse event related to the technique in their clinical careers. The survey did not report that these events were severe, and in the context of moxibustion-adjacent procedures the most common harms are typically minor burns, blisters, and skin irritation at the treatment site. But the near-universality of the experience is itself the finding. It means that adverse events are not rare outliers in warm needle acupuncture practice; they are a routine, expected feature of the procedure as currently performed. For a modality seeking broader clinical and international adoption, that statistic is a red flag aimed squarely at the equipment rather than the concept.

When the researchers asked what stood in the way of more frequent use, the answers converged on three barriers: procedural complexity, safety concerns, and reimbursement limitations. In other words, the doctors surveyed were not doubting whether warm needle acupuncture helps their patients. The constraints they identified are logistical and systemic. The procedure is fiddly and time-consuming to perform correctly, the risk of burns is baked into the current manual method, and insurance coverage does not adequately reward the extra time and skill the technique demands. This distinction matters, because it reframes the problem. If clinicians believed the therapy was ineffective, the solution would be more trials and, potentially, abandonment. Because they believe it works but find it cumbersome and risky, the solution is engineering, standardization, and payment reform.

The survey’s data on future demand make that reframing explicit. A majority of respondents, 70.7 percent, said the top priority should be the development of user-friendly and safe warm needle devices, and 74.9 percent said they would be willing to adopt dedicated devices in their clinics if such tools became available. When asked which features mattered most, 64.7 percent pointed to improved ease of application and 46.7 percent to enhanced safety. Read together, these figures describe a profession that has effectively issued a product specification to the medical device industry: build a warm needle system that a busy clinician can apply quickly, that controls or eliminates the burn risk, and that integrates cleanly into a modern clinic’s workflow, and adoption will follow. The willingness-to-adopt figure is particularly notable, because surveys of clinicians often reveal resistance to new technology; here the resistance runs the other way, toward a technology that does not yet exist in the form practitioners want.

The authors conclude that the clinical utilization of warm needle acupuncture appears to be influenced primarily by procedural and systemic constraints rather than by doubts about its perceived clinical effectiveness. Their prescription is twofold: the development of standardized, safer devices, and appropriate insurance support to make the procedure economically viable in routine care. They also emphasize that further clinical research is required to strengthen the evidence base on both efficacy and safety, a necessary step if the modality is to travel beyond Korean Medicine clinics into international integrative medicine settings, where regulators and insurers demand controlled trial data before a therapy can be recommended or reimbursed.

The broader significance of the study lies in its methodology as much as its findings. Surveys that capture an entire licensed profession, with response data spanning nearly 29,000 invited practitioners, are rare in complementary and traditional medicine research, where evidence often rests on small case series or practitioner anecdotes. By quantifying who uses the technique, who gets burned by it, and what would make them use it more, the Korean team has converted a diffuse clinical impression into a set of actionable targets for device engineers, health insurers, and trial designers. Whether those targets are met will determine whether warm needle acupuncture remains a niche skill passed between experienced hands, or matures into a standardized, safely deliverable therapy that can be studied, insured, and exported on the same terms as any modern medical device.

Subject of Research: Clinical use, safety, and barriers to adoption of warm needle acupuncture in Korean Medicine practice

Article Title: A survey on the current clinical use and perceptions of warm needle acupuncture among Korean medicine doctors

Article References: Kim, M.-G., Sung, W.-S., Kim, E.-J., & Kim, E.-J. (2026). A survey on the current clinical use and perceptions of warm needle acupuncture among Korean medicine doctors. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05592-z

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05592-z

Keywords: warm needle acupuncture, Korean Medicine, moxibustion, acupuncture, adverse events, medical devices, complementary medicine, nationwide survey, reimbursement, clinical practice, traditional medicine, safety